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Abstract
Background: Hepatitis C virus (HCV) is a major cause of chronic hepatitis and a health problem affecting over 170
million people around the world. We previously studied transgenic mice that express HCV Core, Envelope 1 and
Envelope 2 proteins predominantly in the liver, resulting in steatosis, liver and lymphoid tumors, and hepatocellular
carcinoma. Herein, the immune-mediated cell response to hepatitis C antigens was evaluated by adoptive transfers
of carboxyfluorescein succinimidyl ester (CFSE) labelled splenocytes from HCV immunized mice into HCV transgenic
mice.
Results: In comparison to non-transgenic mice, there was a significant decrease in the percentage of CFSE-labeled
CD4
+ and CD8
+ T cells in transgenic mouse peripheral blood receiving adoptive transfers from immunized donors.
Moreover, the percentage of CFSE-labeled CD4
+ and CD8
+ T cells were significantly higher in the spleen of
transgenic and non-transgenic mice when they received splenocytes from non-immunized than from immunized
mice. On the other hand, the percentages of CD4
+ and CD8
+ T cells in the non-transgenic recipient mouse lymph
nodes were significantly higher than the transgenic mice when they received the adoptive transfer from
immunized donors. Interestingly, livers of transgenic mice that received transfers from immunized mice had a
significantly higher percentage of CFSE labeled T cells than livers of non-transgenic mice receiving non-immunized
transfers.
Conclusions: These results suggest that the T cells from HCV immunized mice recognize the HCV proteins in the
liver of the transgenic mouse model and homed to the HCV antigen expression sites. We propose using this
model system to study active T cell responses in HCV infection.
Introduction
Hepatitis C virus (HCV) is a major cause of chronic
liver disease worldwide. The virus causes chronic infec-
tion in 80% of acutely HCV-infected patients; a subset
of these individuals develop progressive liver injury lead-
ing to liver cirrhosis and/or hepatocellular carcinoma
[1,2]. Immune responses to HCV play important roles at
various stages of the infection. There is emerging evi-
dence that the ability of acutely HCV-infected patients
to control the primary HCV infection depends on the
vigorous cellular immune reaction to the virus [3]. In
the chronic phase of infection, immune responses deter-
mine the rate of progression of disease, both by limiting
viral replication and by contributing to immunopathol-
ogy. Livers from chronically HCV-infected individuals
show T cell infiltration; however, these cells are not
HCV specific and are unable to eradicate the virus [4].
These liver-infiltrating lymphocytes are associated with
liver damage in chronic HCV infection via mechanisms
that are not well understood [5]. There are several
immune evasion mechanisms, which might explain the
ability of the virus to escape the immune responses and
establish a persistent infection. These immune evasion
strategies include: virus mutation, primary T cell
response failure, impairment of antigen presentation,
suppression of T cell function by HCV proteins,
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environment in the liver [6]. Nevertheless, the immuno-
logical basis for the inefficiency of the cellular immune
response in chronically infected persons is not well
understood.
Cellular immune responses play a critical role in liver
damage during the clinical course of hepatitis C infec-
tion. HCV-specific CD4
+ T cells are involved in eradica-
tion of the virus in acute infection but their responses
are weak and insufficient in chronic hepatitis [7]. How-
ever, there is no clear evidence that CD4
+ T cells play a
direct role in the liver injury observed during chronic
HCV infection. CD4
+ T cells activate the CD8
+ cyto-
toxic T lymphocyte (CTL) response, which eradicates
the virus-infected cells either by inducing apoptosis
(cytolytic mechanism) or by producing interferon-
gamma (IFN-g), which suppresses the viral replication
(non-cytolytic mechanism) [8]. Enhanced hepatocyte
apoptosis leads to liver damage in chronic HCV infec-
tions [9]. HCV-specific CD8
+ CTL responses are com-
promised in most patients who fail to clear the
infection. In addition, those cells have a diminished
capacity to proliferate and produce less IFN-g in
response to HCV antigens [10]. Those inefficient CD8
+
T cell responses mediate HCV-related liver damage and
are inadequate at clearing the chronic infection.
The mechanisms responsible for immune-mediated
liver damage associated with HCV are poorly under-
stood. One of the mechanisms for liver damage is that
the HCV-activated T cells express the Fas ligand at the
cell surface, which will bind with the Fas receptor on
hepatocytes, initiatiating Fas-mediated signaling, which
may then lead to cell death [11]. HCV core protein
increases the expression of Fas ligand on the surface of
liver-infiltrating T cells leading to the induction of hepa-
tic inflammation and liver damage [12,13]. Another
important mechanism of immune-mediated liver
damage is through CD8
+ T cell-mediated cytolysis. Pre-
vious studies on concanavalin-A-induced hepatitis have
demonstrated that CD8
+ T cells can kill the target cells
in vivo by cytolytic mechanisms mediated by perforin
[14] or requiring IFN-g [15]. This may also involve addi-
tional molecules such as TNF-a [16]; therefore, the level
of cytolytic activity or expression of cytolysis mediators
from the infiltrating lymphocytes could be a determi-
nant for induction of immune-mediated liver damage.
It is still controversial whether the liver damage asso-
ciated with hepatitis C infection is due to the viral cyto-
pathic effects or due to the immune response mediated
damage. Previously, we demonstrated the direct effect of
viral proteins in the pathogenesis of HCV infection by
developing a HCV transgenic mouse model that
expressed the HCV structural proteins, Core, E1 and E2
predominantly in the liver [17]. This model showed
hepatopathy, including hepatic steatosis and liver
tumors. In this study, we describe a model to examine
immune-mediated liver cell damage by means of adop-
tive transfer of splenocytes from HCV immunized mice
into HCV transgenic mice. Our results showed that the
carboxyfluorescein succinimidyl ester (CFSE)-labeled T
cells from HCV immunized mice homed to the liver of
HCV transgenic mice, indicating that these HCV-acti-
vated T cells recognize the HCV transgene and attack
the hepatocytes expressing it, which may lead to liver
damage.
Methods
Mice
All mice used in the study were purchased from the
Charles River Laboratories (Senneville, QC, Canada) and
were from a B6C 3F1 genetic background. Mice were
bred in specific pathogen-free conditions at the animal
care facilities at the University of Ottawa. Animals were
used according to the guidelines of the animal care
committee at the University of Ottawa. Donor mice
were 6 to 8 weeks old; wild type mice and the recipient
mice, both HCV transgenic and non-transgenic mice,
were 3 to 6 months old. The establishment and charac-
terization of these HCV transgenic mice were described
in our previous study [17].
Plasmids and proteins
Construction of pVAX Core, E1 and E2 expression vec-
tor was described in our previous study [17]. Briefly,
total RNA extracted from the plasma of a patient
infected with HCV genotype 1a was used as a template
to amplify Core, E1, and E2 genes. The HCV fragment
containing Core, E1, and truncated E2 genes was con-
structed through RT-PCR using forward primer 5’ ACC
ATG AGC ACG AAT CCT AAA CCTC 3’ and reverse
primer 5’ TGG TAG GGT TGT GAA GGA ACA CG
3’. The amplified fragment was cloned into the EcoR1
sites of pCR 2.1 vector using the TOPO-TA cloning kit
(Invitrogen, Burlington, ON). The nucleotide sequence
was verified by DNA sequencing using the University of
Ottawa DNA sequencing facility. The Core, E1, E2 frag-
ment was subsequently subcloned into pVAX-1 plasmid
(Invitrogen, Burlington, ON) downstream of a cytome-
galovirus promoter. The expression vector of recombi-
nant HCV Core, E1 and E2 polyprotein was also
described in our previous study [18]. Briefly, the TOPO-
TA HCVcore/E1/E2 construct was subcloned into the
pEF6/Myc-His expression vector (Invitrogen Burlington,
ON); this vector contains six histidine residues which
permit purification of the HCV polyprotein by immobi-
lized metal affinity chromatography (Clontech Talon
Metal Affinity Resin Kit, Palo Alto, CA). The recombi-
nant plasmid containing the correctly oriented insert
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using the Endofree plasmid purification kit (Qiagen), as
previously described. Chinese hamster ovary cells were
transiently transfected with the recombinant pEF6/Myc-
His vector containing the core/E1/E2 insert. Transfec-
tion was performed by 2 electroporation shocks at 1.4-
1.6 KV using an electroporation apparatus (BTX Inc.,
San Diego, CA). The transfected cells were incubated in
IMDM (Sigma-Aldrich, St. Louis, MO) containing 10%
FCS (Life Technologies Laboratories, Grand Island, NY)
and 50 μg/mL penicillin-gentamicin. At 65 hrs after
transfection the cells were harvested, lysed in lysis buffer
(25 mmol/L Tris base, 2.5 mmol/L mercaptoethanol,
and 1% Triton-X100), sonicated, and subjected to pro-
tein purification using the Talon affinity resin kit as
described before. The purity of the protein was verified
by mass spectrometry, and protein with ~85% purity
was used for immunization.
Immunization strategy of donor mice
Eight donor mice were immunized with a HCV vaccine
containing pVAX-HCV Core, E1 and E2 DNA (100 μg);
Core, E1 and E2 protein (25 μg) in PBS solution and
montanide (50 μl) ISA-51 (Seppic Inc., Fairfield, NJ) was
used as adjuvant. Mice were immunized three times
with 100 μl of the vaccine and boosted twice intramus-
cularly in the quadriceps major with two weeks intervals
between each boost. Eight wild-type non-immunized
mice were injected with PBS solution and montanide
ISA-51 alone and used as a negative control. After each
immunization, the humoral immune response was
assessed by an IgG ELISA using mouse sera. The cellu-
lar immune response was assessed using PBMCs isolated
from the whole blood after the first immunizations and
using PBMCs isolated from splenocytes after the last
immunization. The mice were anesthetized with 50
Somnotal (MTC Pharmaceuticals, Cambridge, ON,
Canada), sacrificed, and blood and spleens were
collected.
Preparation of lymphocytes from donor mouse spleens
Donor mice were sacrificed using anesthetic, and
spleens were removed and placed in tubes containing
sterile PBS. Lymphocytes were prepared as a cell sus-
p e n s i o nb yg e n t l yp r e s s i n go r g a ns e g m e n t st h r o u g ha
fine plastic cell strainer using a plastic pipette; then, 10
ml of PBS was added to pass cells through the mesh.
The spleen cell suspensions were depleted of red blood
cells (RBC) using RBCs lysis buffer (155 mM NH4Cl, 10
mM KHCO3, and 0.1 mM EDTA). The cellular suspen-
sion was washed three times by adding 0.1% BSA in
PBS and centrifuged at 1600 rpm at 4°C for 5 min. The
cells were counted and divided into 2 parts: cells for
CFSE labeling, which were used for injection and CFSE
proliferation assay, and cells for CTL and ELISPOT
assays used to assess the immune response.
ELISA
To assess the antibody titer against the HCV vaccine,
mice were bled at different points after the immuniza-
tions and the serum was collected. Serum levels of hepa-
titis C-specific antibodies were measured using the HCV
recombinant core/E1/E2 polyprotein as a capture mole-
cule and a mouse-specific monoclonal antibody-horse-
radish peroxidase (HRP) conjugate detection system.
EIA/RIA Stripwell™ plates (Corning CoStar Inc., New
York, NY) were coated with 20 μg/ml recombinant
core/E1/E2 poly protein dissolved in sterile distilled/
deionized water for 4 hrs and incubated overnight at 4°
C. After washing, the plates were blocked with 1% BSA
(Sigma-Aldrich, St. Louis, MO) in PBS for 1 hr at 37°C.
Then the plates were washed and dilutions of sera were
incubated for 2 hrs at 37°C. Antibodies were detected
with a 1/1000 dilution in 1% BSA/PBS of the required
goat anti-species-specific HRP conjugate (IgG H+L:
Jackson Immunoresearch Laboratories, West Grove, PA;
I g G 1 ,I g G 2 a :S e r o t e c ,O x f o r d ,U K ) .A f t e re a c hi n c u b a -
tion time, the plates were washed six times with PBS/
0.05% Tween-20 (Sigma-Aldrich). O-phenylenediamine
dihydrochloride (Sigma-Aldrich) and hydrogen peroxide
were used to develop the color reaction. The optical
density (OD) was read at 490 nm after the reaction was
stopped with 1 N HCl. An IgG2a monoclonal antibody
specific for core protein amino acids 1-120 (Clone 0126,
Biogenesis Ltd., Poole, England) and hepatitis C-negative
or pre-immune sera were run in parallel with all sam-
ples tested as negative control. OD values of at least 2
standard deviations above the mean OD from the pre-
immunization sera were considered positive for an
HCV-antibody response.
IFN-g intracellular staining
CD8
+ CTL responses were assessed by measuring the
mouse IFN-g production using intracellular staining.
The intracellular procedures were done according to
Caltag Laboratories protocol. Briefly, PBMCs isolated
from fresh blood or the splenocytes of immunized mice
were cultured in complete RPMI media in the presence
of 10 μg/ml brefeldin A (Sigma) and stimulated with
core, E1 and E2 protein, core peptides, or vaccinia poly
HCV (NIH AIDS, Cat# 9426) expressing HCV-1 Core,
E1, E2, P7 and NS2 truncated. Unstimulated or empty
vaccinia stimulated cells were used as a negative control.
PMA/ION stimulated cells were used as a positive con-
trol. Eighteen hrs after incubation at 37°C, the cells
were washed with PBS/2% FCS/0.01% sodium azide and
surface-stained for 15 min with PE-labeled monoclonal
antibody against mouse CD3
+, TC-labeled antibody to
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+ or CD4
+ (Caltag Laboratories, Hornby,
ON). The cells were washed as above, fixed and permea-
bilized using Caltag reagent A and B fixation-permeabi-
lization solutions (Caltag Laboratories). The cells were
stained intracellularly with anti-mouse IFN-g FITC-
labeled Ab and incubated for 30 min (in the dark) at
4°C. Following washing, cells were analyzed in a FacScan
flow cytometer (Becton Dickinson, Mississauga, ON).
An increase of 0.1% of IFN-g producing cells over the
unstimulated control or empty vaccinia virus stimulated
cells were considered as positive response to
vaccination.
IFN-g ELISPOT
The ELISPOT assay was performed according to Mab-
tech protocol. Briefly, a 96-well microtiter plate was
coated with mouse anti-IFN-g monoclonal antibodies
(10 μg/ml in PBS). The cells (250,000/well) were added
to the plate with cross bonding stimulants. Cells stimu-
lated with core, E1 and E2 protein, core peptides, or
vaccinia poly HCV. Unstimulated or empty vaccinia sti-
mulated cells were used as a negative control. PMA/
ION stimulated cells were used a positive control. After
48 hrs of incubation, the cells were removed by washing
and a biotinylated antibody against IFN-g (10 μg/ml in
PBS) was added. In the subsequent, the streptavidin
conjugated with enzyme ALP was added. Finally, a pre-
cipitation substrate (BCIP) for ALP was added and the
plates were incubated until spots emerged at the site of
the responding cells. The spots were examined and
counted in an image analyzer system. The mean number
of specific spot-forming cells (SFCs) was calculated by
subtracting the mean number of spots from unstimu-
lated cells or empty vaccinia stimulated cells from the
mean number of spots in cells stimulated with core, E1
and E2 or core peptides or recombinant HCV poly
vaccinia.
Lymphocytes proliferation assay
The CD4
+ T cell proliferation was assessed after labeling
the lymphocytes derived from the spleen using CFSE
dye (Invitrogen Molecular Probes).
Labeling cells with CFSE
Ten mM of CFSE stock solution was prepared by adding
90 μl Dimethyl Sulfoxide (DMSO) to 500 μg lyophilized
powder of CFSE dye. The stock solution was diluted in
sterile PBS/0.1% BSA to get the desired working concen-
tration of 10 μM. Purified lymphocytes were resus-
pended to a concentration of 50 million cells per ml in
PBS/0.1% BSA before the addition of CFSE dye. An
equal volume of 10 μM of CFSE dye was added to the
cell suspension in a tube 6 times more than the volume
of the cell suspension and mixed well by vortexing. The
labeled lymphocytes were incubated for 15 min at 37°C.
The staining was quenched by adding 5 volumes
ice-cold complete RPMI media followed by a 5 min
incubation on ice. The cells were washed three times in
complete RPMI media and re-suspended in complete
RPMI (2 million cells per ml for the proliferation assay
and 40 million cells in 75 μl PBS for injecting to mice).
To verify the CFSE-labeled cells, samples of the cell sus-
pensions were run on a flow cytometer and were also
analyzed by fluorescent microscopy. The proliferation
was assessed after stimulation of the cells with core, E1
and E2 proteins (10 μg/ml) or core peptides (10 μg/ml).
PMA (10 ng/ml) and ionomycine (1 μg/ml) were added
to the cells as a positive control. After adding the stimu-
lant, the cells were incubated at 37° in 5% CO2 for
4 days. The stimulated cells were then harvested by cen-
trifugation at 1600 rpm for 5 min. The prodedures for
statining and manipulation of CFSE labeled cells should
be done in the dark.
Surface stain each stimulated cell with CD3 TC and CD4
PE for 3 colour flow cytometry
The cells were incubated 15 min in the dark at room
temperature. After washing with PBS/0.1 azide/5% FCS,
the cells were immediately analyzed on FacScan or were
fixed by adding an equal volume of 2% paraformalde-
hyde and stored overnight at 4°C before the analysis.
Cells stained with CFSE have very bright fluorescence.
As the cells proliferate, the fluorescence of the cell
populations decreases from bright to dim. Daughter
cells have half the fluorescent intensity of the parent
cell.
Injection of labeled cells into recipient mice
CFSE labeled cells from the donor mice (n = 7) were
pooled and injected through the tail veins of the recipi-
ent mice (n = 7). Twenty million cells suspended in 75
μl of PBS per mouse were injected. The mice were bled
24 hrs after the injection and then sacrificed 7 days
later. The following tissues were collected and processed
for further analysis: blood, lymph nodes, spleen, thymus
and liver.
Flow cytometry
The tissues were processed to get cell suspensions by
gently pressing the tissue through the cell strainer and
collecting the cells in sterile PBS. The RBCs were lysed
from the blood (3-4 times), spleen and lymph nodes
(1 time). The cells were counted and alliquoted and sur-
face stained with fluorescence-labelled antibodies direc-
ted at mouse CD3
+,C D 4
+,o rC D 8
+ for differentiation.
Flow cytometry was carried out on a 4-color flow cyto-
metry instrument (CEPICS XL Flow Cytometry Systems,
Beckman Coulter, Inc). Instrument settings were
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nized controls or negative controls fell within the first
decade of a four decade logarithmic scale on which
emission is displayed. Flow cytometry plots showed at
least 20,000 events. The data were analyzed by FlowJo
software (Tree Star Inc., Ashland, Oregon) in accor-
dance with the manufacturer instructions. The expres-
sion levels of different surface antigen markers as well
as an intracellular proliferating marker were analyzed.
Fluorescence microscopy
Fluorescence microscopy was used to locate lympho-
cytes in intact organs. One to two mm thick sections of
fresh frozen liver and spleen were mounted in mounting
media in a recessed microscope slide and examined
under fluorescence microscopy (excitation at 491 nm
and emission at 518 nm).
Histological analysis
To study the histological changes, mouse livers were
fixed in 4% paraformaldehyde and embedded in paraffin.
Five μm thick sections were stained with hematoxylin
and eosin (H&E) according to standard methods used in
the Department of Pathology and Laboratory Medicine
at the Faculty of Medicine, University of Ottawa.
Statistical data analysis
Statistical analysis used Instat software to do an
ANOVA, followed by Student-Newman-Keuls post hoc
test. Significant differences are based on P < 0.05.
Results
Immune response in HCV-immunized donor mice
We developed a hepatitis C transgenic mouse model in
which the HCV structural proteins are predominantly
expressed in the liver [17]. We used this model to ana-
lyze the kinetics of immune cells featuring an antiviral
immune response against hepatitis C in adoptive trans-
fer experiments after immunization with an HCV vac-
cine candidate. Previously, we showed that mice
immunized with a combinations of a candidate HCV
vaccine consisting of recombinant HCV core/E1/E2
DNA plasmid and rHCV polyprotein and montanide
demonstrated significant humoral and cellular immune
response [18]. In this study, we used the same strategy
to immunize the donor mice. Mice immunized with a
combined HCV vaccine consisting of both HCVcore/E1/
E2 DNA and protein and the adjuvant montanide A51
showed humoral and cellular antiviral immune
responses. The ELISA assay demonstrated a significant
increase in the antibody titer against HCV immunogens.
There was a significant increase in total IgG, IgG1, and
IgG2a after the third immunization at 1:900 antibody
titer (* P < 0.005) (Figure 1). Similarly, in response to
H C Va n t i g e n sC D 4
+ T cell proliferation was demon-
strated by CFSE staining. After the last immunization
the splenocytes were culture di nt h ep r e s e n c eo fc o r e ,
E1 and E2 polyprotein or core peptides. There was a
marked increase in the proliferation response of the
immunized mouse splenocytes when they were stimu-
lated with HCV Core/E1/E2 or core peptides, as indi-
cated by the decrease in the CFSE stain intensity. As the
cells proliferate, the cell population shifts to a lower
intensity due to the decrease of staining in the cell
membranes of proliferating cells. Daughter cells have
half the fluorescent intensity of the parent cells (Figure
2). CD8
+ T cell cytolytic activity was demonstrated by
INF-g production using intracellular staining and ELI-
SPOT. INF-g production was significantly higher in
immunized mice compared to controls (Figure 3, 4).
Approximately 2% of the CD8
+ T cells produced IFN-g
when they were stimulated with HCV core peptide and
1.75% of the cells produced IFN-g when they stimulated
with vaccinia encoding HCV recombinant proteins (vac-
cinia HCV poly) (Figure 3c, d). These results were con-
firmed by IFN-g ELISPOT. It indicated that splenocytes
from immunized mice produced significantly more IFN-
g when they were stimulated with core, E1 and E2 pro-
tein, core peptides or vaccinia encoding HCV recombi-
nant proteins (vaccinia HCV poly) (P < 0.05) (Figure 4).
Flow cytometric analysis of recipient mouse tissues
To study the splenocyte kinetics in the HCV transgenic
mice and to indirectly evaluate the immune response
generated after HCV vaccination, splenocytes from the
immunized and control mice were collected and labeled
with CFSE before performing the adoptive transfer.
CFSE labeled splenocytes were then confirmed by
immunofluorescent microscopy (Figure 5). These cells
were injected intravenously in transgenic and control
mice and tracked down in the blood in vivo after 24 hrs.
Seven days after the adoptive transfer, recipient mice
were euthanized. The location and number of trans-
ferred cells were detected by flow cytometry in blood,
lymph nodes, spleens and livers of recipient mice.
All groups of recipient mice had similar percentages of
donor CD4
+ and CD8
+ T cells at 24 hrs post-adoptive
transfer, indicating that all groups received similar
amounts of donor splenocytes (Figure 6a). Seven days
after the adoptive transfer, the percentage of the donor
CD4
+ and CD8
+ T cells in the blood differed between
the recipient mice receiving immunized and non-immu-
nized donor cells (Figure 6b). There was a significant
increase in the percentage of donor T cells in the blood
of wild type mice receiving immunized donor cells. In
contrast, there was a significant decrease in the percen-
tage of donor T cells in the blood of transgenic mice
having received immunized donor cells. In fact, among
Naas et al. Comparative Hepatology 2010, 9:7
http://www.comparative-hepatology.com/content/9/1/7
Page 5 of 13Figure 1 Humoral immune responses of the donor mice immunized with HCV immunogens as determined by ELISA. Seven mice were
immunized with HCV immunogens containing HCV plasmid DNA, HCV recombinant polyprotein and montanide. Mice were immunized three
times intramuscularly and boosted twice with the same vaccine. After the third immunization, serum samples were collected, serially diluted and
tested for reactivity with HCV core, E1 and E2 protein. Sera were collected from the mice pre-immunization were used as a baseline. Immunized
mice had significant increase in total IgG, IgG1, and IgG2a after the third immunization at 1:900 antibody titer (* P < 0.05).
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Figure 2 CD4
+ T cell proliferation response of HCV-immunized mice. The splenocytes were stained with CFSE dye and incubated with
different stimulants for 4 days. Cells were stained for surface markers using anti-CD3
+ and CD4
+-antibodies and tested using flow cytometry. (A)
Unstimulated cells showing no proliferation, (B) CE1E2 protein-stimulated cells showing proliferation of the cells which is indicated by the shift of
fluoresecence in the cell population (circle), (C) Core peptide stimulated cells showing proliferation. Daughter cells contain half the fluorescent
intensity of the parent cell.
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the lowest percentage of donor T cells in the blood (Fig-
ure 6b). There was no significant difference of donor
cell percentages in the groups receiving cells from non-
immunized donors.
A higher percentage of donor T-cells from the non-
immunized groups homed to the spleen as compared to
the immunized animals. There was a four to ten-fold
increase in the number of CD4
+ and CD8
+ Tc e l l si n
the spleens of mice receiving non-immunized donor
(Figure 7a). The donor cells from immunized animals
homed to the lymph nodes of the wild type mice only.
T h e r ew e r ef e wl a b e l e dc e l l si nt h et r a n s g e n i cl y m p h
nodes. This may be due to alterations in the homing
receptors of the T cells in the transgenic mouse lymph
nodes. The percentages of CD4
+ and CD8
+ T cells in
the non-transgenic recipient mouse lymph nodes were
significantly higher than the transgenic mice when they
received cells from immunized donor mice (Figure 7b).
The proportion of CD8
+ T cells was higher than CD4
+
T cells in lymph nodes of these wild type recipients of
immunized donor mice. There was no difference
between the transgenic and non-transgenic recipient
mouse groups when they received transfers from non-
immunized donors. In contrast to wild-type mice, donor
cells from immunized mice homed to the liver of trans-
genic mice as demonstrated by a three-fold increase in
both CD4
+ and CD8
+ T cells compared to the other
groups of recipient mice (Figure 8). This may indicate a
trapping or homing mechanism for T-cells in transgenic
mouse livers due to the dominant expression of the
HCV transgene.
0.56% 0.45% 1.75% 1.99%
AB C D
I
N
F
γ
γ
-
P
E
CD8-TC
Figure 3 CD8
+ T cells cytolytic activity in the immunized mice as demonstrated by IFN-g intracellular staining. Two weeks after the last
HCV vaccine immunization, cultured splenocytes were unstimulated (A), stimulated with CE1E2 protein (B), core peptide (C), or vaccinia HCV
poly (D). Cells were cultured for 18 hrs in the presence of brefeldin A then stained intracellularly with anti-IFN-g antibody and surface stained
with anti-CD3
+ and anti-CD8
+ antibodies to be analyzed by flow cytometry. Percentages in the upper right quadrant represent the frequency of
CD3
+8
+ T lymphocytes expressing IFN-g. The P value for significant differences was < 0.05.
Figure 4 Detection of CD4
+ and CD8
+ T lymphocyte responses to HCV vaccine in immunized mice using IFN-g ELISPOT assay. ELISPOT
counts (spot-forming units [SFUs]/1 × 10
6) in response to core, E1 and E2 protein, Core peptides, or vaccinia HCV poly. Spot forming cell (SFC)
frequencies are shown after subtraction of background with unstimulated cells or empty vaccinia stimulated cells. Cells were incubated with
core, E1 and E2 protein, Core peptides, or vaccinia HCV poly for 48 hrs before measuring IFN-g ELISPOT responses. Spot forming cell (SFC)
frequency per million cells is indicated for each immunized and non-immunized donor mice. The P value was < 0.05.
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Page 7 of 13Figure 5 Immunofluoresent analysis of CFSE labeled splenocytes before injection. A) CFSE unlabeled splenocytes showing no CFSE
staining. B) CFSE labeled splenocytes showing green fluorescent cells. Scale bar = 50 μm.
Figure 6 Flow cytometric analysis of recipient mouse blood 24 hrs and 7 days post-adoptive transfer. A) The percentage of CFSE CD4
+
and CD8
+ T cells in the blood of the recipient mice 24 hrs post-injection. The × axis indicates the donor and recipient mouse groups (n = 7)
and the Y axis indicate the percentage of the CFSE
+ CD4
+ or CD8
+ T cells B) The percentage of donor CD4
+ and CD8
+ T cells in the blood
seven days after the injection. The cells were surface stained with anti-CD3
+ and anti-CD4
+ antibodies or anti-CD3
+ and anti-CD8
+ and analyzed
by flow cytometry (P< 0.001).
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Page 8 of 13Figure 7 Flow cytometric analysis of recipient mouse spleens and lymph nodes. A) The percentage of CD4
+ and CD8
+ T cells in the
spleens of mice receiving immunized and non- immunized donor cells. B) The percentage of CD4
+ and CD8
+ T cells in the lymph nodes of the
recipient mice. The cells were surface stained with anti-CD3
+ and anti-CD4
+ antibodies or anti-CD3
+ and anti-CD8
+ and analyzed by flow
cytometry (P< 0.001).
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Figure 8 Flow cytometric analysis of recipient mouse livers.T h ep e r c e n t a g eo fC D 4
+ and CD8
+ T cells in the liver of mice receiving
immunized and non-immunized donor cells was detected by FACS. The cells were surface stained with anti-CD3
+ and anti-CD4
+ antibodies or
anti-CD3
+ and anti-CD8
+ and analyzed by flow cytometry (P< 0.001).
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the livers of recipient mice
Immunofluoresence analysis of the liver sections of the
transgenic mice showed infiltration of high number of
the CFSE labeled cells, when they received transfer from
immunized mice (Figure 9a). H&E staining of the liver
sections for the same group of recipient mice showed
infiltration of lymphocytes beside the histological
changes, such as steatosis, due to the expression of
transgenes (Figure 9b). Interestingly, the infiltrated cells
were concentrated in the areas where there was steato-
sis. On the other hand, the transgenic mice receiving
cells from non-immunized donors showed few CFSE
labeled cells on the liver sections and no cell infiltration
was observed in the H&E stained liver section (Figure
10a, b). The non-transgenic mice showed no histological
changes and no infiltration of CFSE labeled cells,
whether they received donor cells from immunized (Fig-
ure 9c, d) or non-immunized mice (Figure 10c, d).
Thus, repetitive transfer of splenocytes from HCV
immunized mice into HCV transgenic mice may be
needed in order to increase inflammation in the liver.
Discussion
In our previous study, we showed an HCV transgenic
mouse model expressing HCV structural proteins (core,
E1 and E2) in the liver [17]. These transgenic mice devel-
oped liver steatosis, hepatopathy and tumor formation
due to HCV protein expression. In this study, we
describe an adoptive transfer from HCV immunized mice
to HCV transgenic mice. As shown previously [18] as
well as in this study, mice immunized with a combination
of a candidate HCV vaccine consisting of recombinant
HCV core/E1/E2 DNA plasmid, recombinant HCV poly-
protein and montanide demonstrate a significant
humoral and cellular antiviral immune responses. In
order to confirm the specificity of the antiviral immune
response and to assist the immune response mediated
liver damage associated with hepatitis C infection, the
splenocytes from the immunized mice were transferred
to HCV transgenic mice. Seven days after the adoptive
transfer, there was a significant decrease in the percen-
tage of CFSE-labeled CD4
+ and CD8
+ T cells in the per-
ipheral blood of transgenic mice that received cells from
immunized donors, whereas the non-transgenic mice
maintained a high percentage of the transferred T cells in
their blood. This indicates that injected cells migrated
from the peripheral blood and homed in different mouse
organs. For instance, the number of CFSE labeled T cells
from immunized mice was significantly higher in the
liver of recipient transgenic mice as compared to those
that received CFSE labeled T cells from non-immunized
Figure 9 Histological alterations in livers from transgenic and non-transgenic mice injected with CFSE-labeled splenocytes from
immunized mice. A) Immunofluorescent analysis of frozen liver sections (5 μm thick) of a transgenic mouse showing CFSE labeled cells scattered
over all the liver section. The fluorescent cells are indicated by arrows. B) H&E stained liver section of transgenic mouse showing steatosis. There is
infiltration of lymphocytes in the liver which is concentrated close to hepatic steatosis (indicated by arrows). C) Immunofluorescence analysis of
frozen liver sections (5 μm thick) of non-transgenic mouse showing no CFSE labeled cells over the liver section. D) H&E staining of liver section of
non-transgenic mouse showing normal histology of the liver and no lymphocyte infiltration. Scale bar = 50 μm.
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Page 10 of 13animals. T cells from HCV immunized mice that selec-
tively homed in transgenic mouse livers, was likely due to
the recognition of HCV transgenes or antigens which are
preferentially expressed in this organ.
The immune responses against pathogens depend on
the ability of lymphocytes to migrate to organs where
t h ep a t h o g e na n t i g e n se x i s t .H e r ew eh a v es t u d i e dt h e
kinetics of transferred lymphocytes in various organs of
recipient mice. The lymphocytes derived from HCV
immunized mice homed in HCV transgenic livers where
the HCV antigens were predominantly expressed. In
contrast, the lymphocytes from naïve mice homed in the
spleen of non-transgenic recipient mice whereas lym-
phocytes from immunized donors homed preferentially
in the non-transgenic recipient lymph nodes. Those
cells are likely activated and perhaps recognize different
homing receptors than lymphocytes from naive animals.
The CD4
+ and CD8
+ T cells from immunized mice
frequently display activation markers. Although activated
cells are more likely to migrate to the liver, more cells
from immunized animals homed in this organ than cells
from naïve animals, suggesting immune specificity
against viral antigens. It was demonstrated that during
adaptive immune responses two types of antigen-
experienced T cells were produced; short-lived effector
T cells, which would home to the sites where the patho-
gen was present, and long-lived memory T cells, that
could provide protection against the pathogen they had
encountered during the previous immune responses
[19]. According to their findings, we hypothesized that
lymphocytes from immunized mice would include both
effector T cells that produced IFN-g and memory
T cells. However, more studies should be done to distin-
guish these in such immune response. Effector and
memory T cells experienced with HCV antigens are the
cells that more likely home to the transgenic livers.
Another fraction of memory T cells stay in the lymph
nodes. HCV-experienced or activated T cells homed in
the lymph nodes of non-transgenic mice because there
was no specific target in the non-transgenic donors. The
increased knowledge on the mechanisms that regulate
lymphocyte homing and imprinting has clear applica-
tions in designing more effective immunotherapeutic
regimens.
There is strong evidence for the important role of
both virus-specific CD4
+ and CD8
+ T cells in HCV
virus clearance as well as in mediating liver cell damage
in chronic hepatitis C infection [20,21]. The two major
Figure 10 Histological alterations in livers from transgenic and non-transgenic mice injected with CFSE-labeled splenocytes from non-
immunized mice. A) Immunofluorescent analysis of frozen liver sections (5 μm thick) of a transgenic mouse showing few CFSE labeled cells
scattered over all the liver section. B) H&E stained liver section of transgenic mouse showing steatosis. There is no infiltration of lymphocytes in
the liver. C) Immunofluorescence analysis of frozen liver sections (5 μm thick) of non-transgenic mouse showing no CFSE labeled cells over the
liver section. D) H&E staining of liver sections of non-transgenic mouse showing normal histology of the liver and no lymphocyte infiltration.
Scale bar = 50 μm.
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Page 11 of 13mechanisms of T-cell mediated lysis are perforin-gran-
zyme-mediated cytotoxicity and Fas-mediated cytotoxi-
city. Both mechanisms can kill the infected cells directly
or by bystander killing which were demonstrated to be
important in hepatic injury [22]. The Fas-Fas ligand sys-
tem is reported to be associated with the killing of the
hepatocytes in patients infected chronically with hepati-
tis C virus. The expression of Fas ligand was up-regu-
lated in the hepatocytes of patients with chronic
hepatitis [23,24]. Liver-infiltrating lymphocytes express
Fas ligand which will bind with the Fas receptor on the
surface of hepatocytes and initiate Fas-mediated cell
death [11,25]. In previous studies it has been shown that
CD8
+ T cells can kill the targets in vivo by cytolysis
mechanisms mediated by perforin and TNF-a [14] or
required IFN-g [15,22]. There are several experimental
models of immune-mediated liver damage in chronic
hepatitis. Adoptive transfer models using transgenic ani-
mals expressing HBV proteins in hepatocytes have been
previously described [26,27]. These mice develop toler-
ance to virus-encoded proteins, but infusion of non-tol-
erant T cells will cause liver inflammation. Despite that
some studies using in vitro systems showed that HCV
structural, core and E2 proteins, were able to cause
immunosuppression [28-30], there is no evidence show-
ing that transgenic mice expressing HCV core, E1 and
E2 proteins have global immunosuppression [31].
Conclusions
We were able to adoptively transfer non-tolerant T cells
i n t oat r a n s g e n i cm i c ee x p r e s s i n gH C Vt r a n s g e n ei n
hepatocytes. The transfer results in rapid and selective
accumulation of the activated T cells in the liver of the
transgenic mice but not in mouse spleen or lymph
nodes. In this study we did not detect the fate of the
transferred cells; nonetheless, it seems that these cells
have the potential to have an antiviral effect that may
result in liver inflammation and, subsequently a more
severe injury.
Moreover, we suggest that performing adoptive trans-
fer of splenocytes from HCV immunized mice into
H C Vt r a n s g e n i cm i c em a yp r o v i d eag o o dm o d e lt o
study the mechanisms of hepatic injury in chronic hepa-
titis C infection. This study may potentially help the
development of an immunotherapeutic strategy for HCV
infection.
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